RecruitingNCT05650125

A Platform Study for solId orgaN CancERs

PINCER (A Platform Study for solId orgaN CancERs); an Agile Regional Platform Study to Deliver High Quality Translational Research


Sponsor

University of Liverpool

Enrollment

2,000 participants

Start Date

Jan 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Generating bespoke biosampling protocols for individual tumour specific translational projects is onerous, cumbersome and inefficient. This study aims to provide a broad platform to maximise the unique access to biopsy and resected tumour specimens available from cancer patients to provide a high-quality and efficient source of biosamples for specific translational projects. Access to historical FFPE samples and clinical data, as well as prospective fresh tissue samples, will allow interrogation of the underlying biology of these cancers. Matched pseudoanonymised clinical and radiological data will allow the development of rich high-yield datasets.


Eligibility

Min Age: 16 YearsMax Age: 100 Years

Inclusion Criteria1

  • Biopsy or surgical resection as standard of care

Exclusion Criteria1

  • Refusal or inability to consent, paediatric patients

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBiosampling

Biosampling of blood/tumour/adjacent normal tissue


Locations(1)

University of Liverpool

Liverpool, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05650125


Related Trials